Ramiven 150mg (Abemaciclib) is a medication used to treat certain types of breast cancer, including:
- Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 (HER2)-negative breast cancer
- Hormone receptor-positive (HR+) and HER2-negative breast cancer that has progressed after treatment with other medications
Composition:
Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor, which means it works by blocking the activity of CDKs, which are proteins that help regulate cell growth and division.
Mechanism of Action:
Abemaciclib works by inhibiting the activity of CDKs, which helps to:
- Slow down the growth of cancer cells
- Prevent cancer cells from dividing
- Reduce the production of proteins that help cancer cells grow
Indications:
Ramiven 150mg (Abemaciclib) is indicated for the treatment of:
- Hormone receptor-positive (HR+) and HER2-negative breast cancer in combination with fulvestrant in women who have received prior endocrine therapy
- Hormone receptor-positive (HR+) and HER2-negative breast cancer in combination with letrozole in postmenopausal women
Dosage:
The recommended dosage of Ramiven 150mg is:
- 150 mg taken orally twice daily, with or without food
Side Effects:
Common side effects of Ramiven 150mg include:
- Nausea
- Diarrhea
- Fatigue
- Abdominal pain
- Headache
- Muscle pain
- Joint pain
- Skin rash
- Hair loss
- Increased liver enzymes
Contraindications:
Ramiven 150mg is contraindicated in patients who have:
- A history of severe allergic reactions to the medication
- A history of severe diarrhea or gastrointestinal perforation
- Uncontrolled diarrhea or abdominal pain
- Severe liver disease or liver failure
Important Note:
Ramiven 150mg is a prescription medication and should only be used under the supervision of a qualified healthcare professional. Patients should be advised to monitor their blood counts and liver function regularly during treatment.
Reviews
There are no reviews yet.